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Abstract 
 Two targets were set for the current work: exploiting the effect of the targeting ligand 4-
aminophenyl-alpha-D–manno-pyranoside (PAM) in enhancing the uptake of nanoliposomes (NL) 
by alveolar macrophages and investigating the efficiency of NL co-spray drying with the carrier 
biomacromolecule dextran (DX) for improved physical stability and lung deposition. 
Moxifloxacin (MXF) loaded NL were prepared by reversed phase evaporation method using 
different lipids and the surface of selected NL was decorated with PAM. Selected NL formulations 
were co-spray dried with dextran (DX) to yield surface modified NL embedded in microparticles 
(SD-NLEM). Using the proportion method, the antibacterial activity against resistant M. 
tuberculosis was tested. The safety of the developed system was tested on lung cancer cells and 
the uptake by alveolar macrophages was followed using flow cytometry measurements. 
Fluorescently labeled NL were tracked in vivo in rats to test lung deposition following pulmonary 
administration. The results showed that spray drying efficiently enhanced the stability and 
morphological characteristics of the optimized monodisperse NL achieving a respirable particle 
fraction of more than 75%. Deep lung deposition was confirmed in rats. Charged NL provided 
higher anti-tubercular activity and macrophage uptake compared to the neutral ones. 
Mannosylation efficiently increased active uptake by alveolar macrophages uptake.  
Keywords:  Nanoliposomes; lung targeting; macrophages; spray drying; aminophenyl-manno-
pyranoside; microparticles; tuberculosis. 
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List of abbreviations 
Association efficiency AE 
Colony forming unit  CFU 
cholesterol  CH 
Geometric mean diameter d  
Dicetyl phosphate  DCP 
Dimethyl sulphoxide  DMSO 
N-[1-(2, 3- dioleoyloxy)propyl]-N,N,N-trimethyl ammonium chloride  DOTAP 
Dextran sulphate  DX 
Encapsulation efficiency EE 
Emitted fraction EF 
Effective inhalation index  EI 
Fetal bovine serum FBS 
Fkuorescence intensity FI 
Fluorescein isothiocyanate  FITC 
Fine particle fraction FPF 
Leucine Leu 
Mass of the capsule after simulating the inhalation  mempty 
Mass of the capsule before simulating the inhalation  mfull 
Minimal inhibitory concentration  MIC 
Mass median aerodynamic diameter MMAD 
Microparticles MP 
Mass of the powder in the capsule mpowder 
Moxifloxacin hydrochloride  MXF 
NL to carrier ratio NL/C  
Nanoliposomes embedded in microparticles NLEM 
4-aminophenyl-alpha-D–manno-pyranoside  PAM 
Phosphate buffer solution  PBS 
L-α-phosphatidylcholine  PC 
Phosphatidyl-ethanolamine  PE 
Particle size  PS 
Revolutions per minute rpm 
Spray dried SD 
Scanning electron microscopy SEM 
Fraction (%) distributed to stage 2 St2 
Transmission electron microscope TEM 
Twin stage glass impinger  TSI 
Volume mean diameter  VMD 
Amount of free drug detected in supernatant  Wfree drug 
Total amount of the drug used Winitial drug 
Zeta potential  ζ 
Wavelength of maximum absorption λmax 
Tapped density ρ 
Reference density of 1g/cm3 ρ0 
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1. Introduction 
Tuberculosis (TB), the second most common cause of death worldwide is caused by the 
gram positive aerobic intracellular bacteria, mycobacterium tuberculosis (M. tuberculosis) [1]. 
Although, it affects many organs yet, in 80% of cases, the disease is confined to the lung causing 
a severe lifelong communicable respiratory infection called pulmonary TB. The efficacy of 
therapy of TB is usually constrained by drug dosage, first pass effect, systemic adverse effects 
specifically reduced liver and kidney functions, inadequate distribution to pathological sites, in 
addition to the emergence of drug resistance. The residence and proliferation of M. tuberculosis 
in alveolar macrophages (AM), within secreted waxy complex cellular envelope, resisting 
treatment, contribute to the difficulty of tuberculosis eradication [2, 3].  
Inhalation therapy has emerged as a valuable approach for the site specific treatment [2-5]. 
However, for effective lung targeting, specific attributes of size, surface characteristics, and 
aerodynamic properties with the ability to evade the lung defense mechanisms should be 
considered while designing the carrier [6]. In this context, liposomes exhibit potential 
characteristics for lung delivery. Beside their biocompatibility, amphiphilic character, 
biodegradability, and low immunogenic potential, liposomes are formulated from natural or 
synthetic phospholipids that are similar to endogenous lung surfactant which make them an ideal 
pulmonary delivery carrier [7]. With the versatility of phospholipid molecules used for their 
fabrication, it has been possible to tailor liposomes with specific particle size (PS), surface charge 
and physiochemical characteristics to passively target a particular region in the RT, in this study 
the alveolar macrophages (AM) [8].  
Moxifloxacin hydrochloride (MXF) is a fourth generation fluoroquinolone with dual 
antimicrobial mechanism of action [9]. It is effective against drug susceptible and multi drug 
resistance TB [10, 11] . Encapsulation of MXF in vesicular delivery systems was thought to 
improve the efficiency of TB treatment. Anchoring a mannose derivative on the NL surface is 
thought to boost the macrophage targeting efficiency besides the specially designed liposomes 
characteristics.   
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However, poor scale-up, cost, short shelf life, and in some cases toxicity are among 
reported liposomes shortcomings [12]. To enhance their stability and meet the aerodynamic 
characteristics, inherently required for lung targeted delivery systems, spray drying of liposomes 
using suitable carriers that can preserve them during dehydration, offers an attractive option to 
provide dry microparticles (MP) suitable for inhalation [8, 13]. Upon contact with pulmonary fluid 
these MP dissociate into NL, combining the ability of MP lung deposition with NL advantages 
[14]. 
Hence, the ultimate target of this work was to ensure the fabrication of stable liposomes 
encapsulating MXF with efficient lung delivery characteristics. We hypothesized that by tuning 
the size, charge, composition of liposomes as well as anchoring surface ligand, PAM, better 
targeting of antitubercular drugs to the AM could be achieved. Co-spray drying NL with a 
biocompatible fast dissolving polysaccharide, dextran, was implied to enhance physical stability 
and lung delivery characteristics [6]. Comparative studies relating in vitro lung deposition using a 
twin stage impinger to in vivo deposition using a dry powder insufflator is also presented in this 
work. The developed targeted nanocarrier platform is expected to have great potential for 
improving drug cure in case of intracellular infectious diseases.  
2. Materials and methods 
2.1. Materials 
 Moxifloxacin hydrochloride (MXF) was kindly provided by Medical Union 
Pharmaceuticals Company (Egypt). L-α-phosphatidylcholine (PC), type X-E, from dried egg yolk, 
cholesterol (CH), dicetyl phosphate (DCP), 4-aminophenyl-alpha-D–manno-pyranoside (PAM), 
glacial acetic acid and phosphotungstic acid were from Sigma (UK). N-[1-(2, 3- 
dioleoyloxy)propyl]-N,N,N-trimethyl ammonium chloride (DOTAP) and phosphatidyl-
ethanolamine (PE) from egg yolk were from Lipoid (Germany). Dextran sulphate (DX) (MW 
500,000), dimethyl sulphoxide (DMSO) ≥99.9% and fluorescein isothiocyanate (FITC) from 
Sigma (UK). Leucine from Fluka, (Switzerland). Glutaraldehyde solution, 25% in water, from 
Chemie GmbH, Germany. All other chemicals and reagents were of analytical grade. 
2.2. Preparation of MXF- loaded nanoliposomes (MXF-NL) 
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 Various phospholipids, PC or PC/PE, to CH molar ratios were used for the preparation of 
liposomes applying the modified reverse phase evaporation (REV) method [15]. DCP and DOTAP 
were used to impart negative and positive charge, respectively [16-18]. Briefly, lipids were 
dissolved in 2:1v/v chloroform/methanol mixture in a round bottom flask at a concentration of 
2%w/v and the organic solvent was removed by rotary evaporator (Janke and Kunkel, IKA 
Laboratories, Staufen, Germany) at 40˚C. The obtained film was dissolved in 12 mL diethyl ether 
and MXF, dissolved in 10 mL PBS, pH 7.4, was added to the lipid mixture which was bath-
sonicated for 5 min. The organic solvent was again removed under reduced pressure at 40˚C using 
a rotary evaporator, rotating at approximately 200 rpm, until a gel was formed. Upon further 
vigorous rotary evaporation (300 rpm), the resultant gel was broken to give the liposomes. The 
remaining aqueous phase (16 mL PBS, pH 7.4) was then added portion wise with gentle vortex 
mixing. Then the flask was stirred at ambient temperature on rotary evaporator at 200 rpm for 45 
min. The formed liposomes were passed through a stack of polycarbonate membrane with defined 
pore size (400nm) using an extruder (Lipex extruder, Avestin Inc.). The liposome suspension was 
left to mature overnight at 4°C to ensure hydration of the lipid. The effect of varying the buffer pH 
was also evaluated. Table 1 shows the composition of the developed formulae.  
 
2.3. Preparation of MXF loaded mannosylated NL (MXF-PAM-NL) 
 The targeting biomacromolecule PAM was conjugated to the optimum PE containing NL 
adopting gluteraldehyde cross-linking method [19, 20]. Briefly, an amount of 1mL of liposomal 
dispersion in PBS, pH 7.4, was mixed with 2mL of 1% w/v aqueous PBS solution of PAM. 
Glutaraldehyde was added slowly to the liposomal suspension at a final concentration of 3mM and 
the mixture was incubated for 5min at 20°C [20]. Dynamic dialysis technique against 1liter PBS 
solution at room temperature was performed to remove the uncoupled glutaraldehyde with 
replacement of PBS every 30min [21].  
2.4. Preparation of spray dried nanoliposomes embedded in microparticles (SD-NLEM)  
Freshly prepared NL were dispersed in 50mL deionized water containing 10mg/mL of the 
biomacromolecular carrier (DX) as bulking agent ± Leu as dispersing aid. The dispersions were 
then spray dried using a Buchi-290 spray dryer (Buchi Laboratorium, AG, Switzerland) at air flow 
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rate of 473 L/h and a nozzle atomizer diameter of 0.7mm. A pump capacity of 5% and aspiration 
rate of 85% at an inlet temperature of 80˚C were applied. The spray dried powders (SDP) were 
collected and stored in a vacuum desiccator at room temperature for further analysis.  
2.5. NL characterization 
2.5.1. Determination of drug encapsulation efficiency (EE) 
Drug EE in NL was determined indirectly by measuring the concentration of the free drug 
in the supernatant following centrifugation of NL dispersion placed in Nanosep®  (MWCO 
100KDa; Pall Life Sciences, USA), at 9000rpm for 90min at 4°C in a cooling centrifuge (Bench 
Biofuge, Heraeus, Germany). The amount of free MXF in the supernatant was estimated 
spectrophotometrically at predetermined λmax, (289nm), using UV-visible spectrophotometer 
(Model UV-1601PC; Shimadzu, Kyoto, Japan.) and EE was calculated according to the following 
equation:  
 EE% = {(Winitial drug- Wfree drug)/ Winitial drug} x100                           (1) 
Where "Winitial drug" is the total amount of the drug used and "Wfree drug" is the amount of free drug 
detected in supernatant after centrifugation of the aqueous dispersion. 
2.5.2. Particle size (PS) and zeta potential (ζ) determination 
PS analysis and ζ were determined using Zetasizer Nano ZS (Malvern Instruments Ltd, 
Malvern, UK) as previously described elsewhere.  
2.5.3. Morphological examination by transmission electron microscope 
  A drop of NL dispersion was applied on carbon-coated copper grid for 2–3min and the 
excess was then drawn off with filter paper [22]. A drop of 2% (w/v) phosphotungstic acid was 
subsequently placed to the grid. Negatively stained NL were examined by TEM (Hitachi-H-600, 
electron microscope, Jeol, Japan), at a power of 120 kV. 
2.5.4. Proton magnetic resonance (1H-NMR) 
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The incorporation of PAM in the NL was confirmed by 1H-NMR. The prepared NL, 
purified by dialysis, were then separated by centrifugation using Nanosep®, left to air dry and then  
dissolved in DMSO by vortex mixing for 48h. The 1H-NMR scan was done at a frequency 
400MHz, pulse width 12W and scan number 16. 
2.6. SD-NLEM characterization 
 The spray drying yield and powder moisture content were determined according to 
methods described in supplementary information (SI) section [23]. 
2.6.1. PS determination and mass median aerodynamic diameter calculation 
PS was determined adopting the wet dispersion method using Laser diffraction-Malvern 
Mastersizer S (Malvern instrument-UK). Isopropanol was employed isopropanol as antisolvent  
and PS was expressed as the volume mean diameter (VMD) and the span [7, 24]. The mass median 
aerodynamic diameter (MMAD) was then calculated according to the following equation. 
        MMAD =  !	#ρ/ρ0                                           (2)  
Where d is the geometric mean diameter obtained from PS analysis, ρ is the tapped density and ρ0 
is the reference density of 1g/cm3 [25]. Selected MXF loaded SD-NLEM were stored in desiccator 
over silica gel at room temperature for six months. Samples from each batch were withdrawn at 
specified time intervals to determine the PS. 
2.6.2. NL recovery from SD-NLEM 
An amount of 10mg of SDP was dispersed in 3mL of PBS, pH 7.4 and vortexed for 1min. 
The size of the dispersed particles Sf was determined using Zetasizer and was compared to the 
initial size of the NL before spray drying (Si). The value of Sf/Si ratio close to unity indicates full 
redispersibility [26-28]. 
2.6.3. Drug association (AE) and encapsulation efficiency (EE) determination 
An accurately weighed amount of SDP was dissolved in 30%v/v aqueous methanolic 
solution and the AE was determined as % from theoretical drug content. EE of MXF in SD-NLEM 
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was determined indirectly by measuring the concentration of the free drug in the aqueous phase 
following re-dispersion of an accurately weighed amount of SDP in PBS, pH 7.4.  
 2.6.4. In vitro aerodynamic deposition of SD-NLEM 
The aerodynamic deposition was evaluated using the twin stage glass impinger (TSI) 
(Copley, Nottingham, UK). The upper and lower impingement chambers of the TSI were filled 
with 7 and 30mL of 30% v/v methanol in water, respectively. Aliquot of the SDP (15mg) was 
loaded in HPMC No 3 capsules and placed in the Aerolizer®, attached to the throat of the impinger 
via the adaptor and the test was performed as previously described [5, 29]. Drug content of the 
powder collected on each stage was determined spectrophotometrically. In vitro aerosolization 
properties of the SDP was described by the following terms: emitted fraction EF, determined 
gravimetrically, and defined as the total amount of powder emitted from the inhaler as a percentage 
of the amount of powder loaded in the capsule, expressed as: 
EF = 
((	)*++,(	-(./0)(	.234-5 6100                                 (3) 
Where mfull and mempty are the masses of the capsule before and after simulating the inhalation 
respectively and mpowder is the mass of the powder. Respirable particle fraction (RP), which is a 
percentage of drug deposited on lower stage of TSI against the particles emitted from the  
inhalation system (emitted fraction) and effective inhalation index (EI), were also calculated using 
the following equations:  
RP %= (892 ;<⁄ )6100                                     (4) 
EI % = √8926;<                                                (5) 
Where Em is the fraction (%) emitted from the inhalation system, and St2 is the fraction (%) 
distributed to stage 2 of the TSI. For an ideal DPI, the EI and RP are 100% [30]. 
2.6.5. Surface morphology of SD-NLEM 
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The surface morphology of selected SDP was examined using scanning electron 
microscopy; SEM (Model Quanta 250 FEG, FEI company, Netherlands) as previously described 
[7].  
2.6.6. In vitro MXF release from SD-NLEM 
In vitro MXF release was performed adopting the dialysis membrane diffusion technique.  
Briefly, an accurately weighed amount of SD-NLEM was suspended in 0.5mL PBS (pH=7.4) in a 
dialysis bag immersed in vial containing 3mL PBS (pH 7.4). The vials were placed in a shaking 
water bath at 37±0.5°C rotating 50strokes/min. At predetermined time intervals, samples were 
withdrawn, replaced with fresh buffer, and assayed spectrophotometrically at 295 nm for MXF 
content.  
2.6.7. Antibacterial activity of MXF-NLEM 
The antibacterial effectiveness of blank and MXF-NLEM was assessed in comparison to 
the free drug by measuring the minimal inhibitory concentration (MIC) against M. tuberculosis. 
The proportion method using Lowenstein-Jensen medium was adopted [31]. The MIC (μg/mL), 
the lowest concentration that inhibited more than 99% of visible bacterial growth of initial 
inoculum, was determined by counting the number of colony forming unit (CFU) in each vial and 
comparing them with the growth in the control vial [32]. The experiment was performed in 
triplicate. 
2.6.8. Cytotoxicity evaluation by MTT assay 
Cytotoxicity of selected formulae was evaluated using MTT assay on lung cancer cells 
(A549) [33]. Serial two fold dilutions from 25 to 0.78μg/mL of the drug solution, equivalent 
amounts of drug loaded formulae and their blanks were prepared. A control of untreated cells was 
made in the absence of test compound. The absorbance of untreated cells was considered as 100%. 
The results were determined by three independent experiments performed in triplicate (n=9) and 
the cell viability was calculated as previously described [34, 35].  
2.6.9. In vitro phagocytosis of NL using mice macrophages J774A.1 
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FITC-labeled NL were first prepared as previously described while replacing MXF 
solution by FITC solution (0.2mg/mL). Dynamic dialysis technique against PBS solution at room 
temperature, until no fluorescence was detected in the dialysate, was performed to remove the 
unentrapped FITC.  
Murine monocytes macrophages of cell line J774A.1 were used to study the potential of 
macrophage uptake of NLEM. The cells were maintained in complete medium consisting of 
DMEM supplemented with10% fetal bovine serum (FBS), 2mM-glutamine and 0.1%w/v 
penicillin-streptomycin solution and incubated at 37˚C and 5% CO2 atmosphere. Aliquots (500μL) 
of J774A.1 cells (5x104) cells were seeded in each well of a 24 wells plate on glass cover slips 
coated with poly-D-lysine. The plate was incubated for 24h and then washed with DMEM-L-
glutamine to remove non-adherent cells. Subsequently 500μL of DMEM-L-glutamine containing 
0.25 or 0.5mg/mL of FITC- SD-NLEM (corresponding to lipid concentrations 75 and 150μg/mL) 
were added to the cells in each separate well. The cells were incubated with the particles for 30 or 
180 min [36]. The medium was then aspirated and the cells were washed twice with PBS to remove 
the particles adhering to the cell surface. Subsequently the cells were fixed with 4% 
paraformaldehyde solution for 30min at room temperature then washed twice with PBS. The cells 
associated fluorescence was measured by fluorescence activated cell sorter (FACS) (BD 
Biosciences). Cells incubated without addition of FITC loaded particles were used as control to 
determine the auto-fluorescence. Fluorescence intensity was used as indicator of the amount of 
cellular uptake.  
 
2.6.10. In vivo pulmonary deposition study 
For all animal studies, the experimental procedures conformed to the Ethics Committee of 
Faculty of Pharmacy, Ain Shams University on the use of animals. Male albino rats were housed 
in an environment with a controlled temperature (21-24˚C) and lighting (12:12h light-darkness 
cycle).  
In vivo deposition studies of FITC-loaded SD-NLEM were performed as previously 
reported [37, 38]. An accurately weighed dose of about 5mg of FITC-loaded SD-NLEM (formula 
SD-PC) were delivered intra-pulmonary using the low scale dry powder inhaler (DPI) (Model DP-
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4 from Penn-century®). The rat's abdominal cavity was incised immediately after powder 
administration, then a catheter connected to an infusion pump was inserted in the posterior vena 
cava. The lungs were treated consecutively with two infusion solutions. The first infusion was 
done at a rate of 10mL/min for 5min with PBS pH7, then the lung was perfused with 4% 
formaldehyde at 5mL/min for 5min for fixation. The lung was then removed and cross sectioned 
(section thickness~30μm). For each part (trachea, bronchus, bronchioles and alveolar ducts), 3-5 
slides were prepared and examined by fluorescent microscope (Olympus U-RFL-T, BX51, 
Olympus, Berlin, Germany) [38]. A control experiment was run to assess the auto-fluorescence of 
rat lung tissue in which rat had not received any powder and tissues were rinsed and fixed as 
mentioned above. 
 
2.7. Statistical analysis 
All formulations were prepared and reported in triplicate. Results are expressed as mean ± 
s.d. (standard deviation).The statistical significances of difference between groups were evaluated 
by one-way ANOVA and Tukey's post hoc test with a significance level of p<0.05. 
3. Results and discussion 
3.1 Optimized MXF–NL using various lipids 
Trying various PC/CH molar ratios (10:0, 9:1, 8:2, 7:3, 6:4, and 5:5) for the preparation of 
MXF-NL revealed that the absence of CH in the formulation led to high PS (371.98 ±6.98nm) and 
PDI (0.645 ±0.039) with low EE (27.45±3.57%), Table 1. Smaller PS and PDI were seen 
following its incorporation, Fig.1S. CH increases stability and rigidity of the liposomal membrane 
during hydration, enhances microviscosity of the lipid bilayer, reduces permeability and acts as 
crystal-breaker of the gel phase and induces of chain-ordering in the fluid phase without 
rigidification of the overall phase [39, 40]. Increasing CH level, up to PC/CH molar ratio7:3, led 
to significant EE increase ascribed to the ability of CH to cement the leaking spaces in the 
phospholipid bilayers. Conversely, at higher CH level (PC/CH 6:4 and 5:5), the EE decreased 
probably due to a disruption in the regular bilayer structure leading to leaching of drug lowering 
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its entrapment [41-43]. Hence, a molar ratio of (7:3) of PC/CH was found optimum; at this level, 
the highest EE (66.25±1.89%) was seen with a MXF to total lipids ratio of 0.15:1.  
 The use of PE caused significant PS increase as evidenced by comparing PE1 to PC8. 
Increase PE conc resulted in slight significant increases in PS and EE as seen in PE2, followed by 
formation of a heterogenous liposomal dispersion with higher PDI (0.483±0.049) and PS 
(580.5±11.53nm) and lower EE (53.32 ±1.89%), as seen with PE3. The reported instability of PE 
and its rapid phase transition to non-bilayer (hexagonal phase II) structures could account for this 
observation [20]. This was probably overcome  by the stabilising effect of PC and CH at lower 
PE/PC ratios [39]. The noted decreased ζ in PE formulae especially PE3 might also have 
contributed to the liposomes instability and aggregation. Formula PE2 was selected for subsequent 
surface modification with PAM. 
Various PC/DCP ratios were used to prepare anionic at 7:3 lipid /CH ratio. No significant 
difference (p>0.05) was seen in PS while a significant (p<0.05) reduction in EE was noted. 
Decreasing the pH to 5.5 led to a slight, though significant, increase in EE which reached 62.05 
±2.19%. The ionization of MXF amino group at pH 5.5 resulted probably in a strong electrostatic 
attraction between the negatively charged DCP and the drug cation [44], an effect which was not 
seen with other lipids. A higher negative ζ compared to formula PC prepared without DCP pointing 
out to their possible higher stability.   
DOTAP alone or in combination with PC was used to prepare cationic MXF-NL. The 
lowest PDI (0.242 ±0.002) and the highest MXF EE (56.62±2.44%), were seen with DP3 prepared 
with DOTAP/PC/CH ratio of 3.5:3.5:3 at pH 7.4. 
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Table 1: Composition and characterization of MXF-nanoliposomes.  
V
ar
ia
bl
e 
pH Formula 
Formula composition 
 
PS (nm) 
 
PDI 
 
EE (%w/w) 
 
ζ (mV) PC: PE:DCP:DOTAP: CH  
(molar ratio) 
MFX(a)  
 
PC
:C
H
  
7.4 
PC1 10:0:0:0:0 0.1 372 (7.0) 0.65 (0.04) 27.45 (3.57) -7.85 (0.78) 
PC2 9:0:0:0:1 0.1 244 (1.8) 0.56 (0.09) 34.39 (2.19) -9.84 (0.55) 
PC3 8:0:0:0:2 0.1 265 (2.6) 0.43 (0.01) 50.19 (2.04) -12.45 (0.74) 
PC4 7:0:0:0:3 0.1 272 (1.6) 0.29 (0.01) 53.94 (2.53) -12.08 (0.97) 
PC5 6:0:0:0:4 0.1 323 (10.0) 0.39 (0.02) 40.36 (2.02) -11.12 (0.45) 
PC6 5:0:0:0:5 0.1 380 (12.3) 0.63 (0.05) 35.28 (2.85) -10.21 (0.81) 
M
X
F 
lo
ad
in
g 
7.4 
PC7 7:0:0:0:3 0.05 266 (5.8) 0.38 (0.04) 42.07(5.32) -11.93 (0.55) 
PC8 7:0:0:0:3  0.15 277 (2.2) 0.30 (0.02) 66.25 (1.89) -12.31 (0.76) 
PC9 7:0:0:0:3 0.2 281 (1.3) 0.29 (0.01) 50.96 (1.57) -11.52 (0.66) 
PC10 7:0:0:0:3 0.3 285 (2.6) 0.32 (0.03) 33.53 (2.33) -11.42 (0.51) 
PE
 
co
nc
 
7.4 
PE1 6:1:0:0:3 0.15 299 (4.1) 0.25 (0.01) 61.66 (2.73) -8.03 (0.35) 
PE2 5:2:0:0:3  0.15 313 (6.0) 0.30 (0.04) 63.59 (2.52) -6.54 (0.41) 
PE3 4:3:0:0:3 0.15 580 (11.5) 0.48 (0.05) 53.32 (1.89) -4.25 (0.38) 
PC
:D
C
P  
7.4 
DC1 6:0:1:0:3 0.15 273 (1.2) 0.25 (0.01) 57.58 (2.02) -31.32 (0.35) 
DC2 5:0:2:0:3 0.15 274 (0.7) 0.26 (0.03) 46.99 (1.62) -29.51 (1.63) 
5.5 DC3 6:0:3:0:1 0.15 273 (3.3) 0.24 (0.01) 62.05 (2.19) -27.82 (2.76) 
PC
:D
O
TA
P 
7.4 
DP1 0:0:0:1:1 0.15 333 (3.3) 0.33 (0.03) 44.47 (1.49) 25.42 (0.28) 
DP2 0:0:0:7:3 0.15 325 (3.8) 0.27 (0.02) 50.61 (1.58) 26.03 (1.76) 
DP3 3.5:0:0:3.5:3  0.15 320 (6.4) 0.24 (0.01) 56.62  (2.44) 23.82 (0.64) 
PA
M
 
7.4 PE-PAM 5:2:0:0::3 0.15 379 (3.6) 0.30 (0.05) 62.18 (2.08) -4.12 (0.32) 
(a): Calculated as mole/mole of total lipids. PC: egg phosphatidylcholine, CH:  Cholesterol, PE: phosphatidyl ethanolamine, DCP: dicetyl phosphate, DOTAP: N-
[1-(2, 3- Dioleoyloxy) propyl] -N, N, N- trimethyl ammonium chloride, and MXF: moxifloxacin hydrochloride. Results are mean of three determinations 
(s.d.).formulae selected for subsequent studies are shown in bold. 
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Table 2: Characteristics of MXF loaded spray dried nanoliposomes embedded in microparticles (MXF-SD-NLEM). 
. 
Size increase 
(%) Sf/Si 
Moisture 
(%w/w) MMAD (µm) Span 
D[4, 3]  
(µm) 
AE 
(%w/w) 
%EE (f)(c) 
(%w/w) 
Yield 
(%w/w) NL:C
(b) Leu
(a) 
(%w/w) Formula 
- -  4.76 (0.12) 2.62 (0.29) 7.32 (0.05) - 64.75 (1.59) 46.78 (4.39) 
1:20 
0 S1 
- - - 1.62 (0.01) 0.95 (0.04) 2.69 (0.03) - 63.76 (2.01) 67.25 (4.01) 20 S2 
- - - 1.47 (0.05) 1.48 (0.51) 2.86 (0.04) - 62.54 (2.47) 69.37 (5.15) 30 S3 
- - - 1.78 (0.09) 1.35 (0.03) 3.31 (0.02) - 61.35 (1.87) 75.19 (2.94) 40 S4 
- - - 2.04 (0.09) 1.26 (0.05) 3.84 (0.19) - 60.29 (1.94) 80.21 (3.93) 50 S5 
- - - 3.73 (0.15) 1.22 (0.04) 6.97 (0.09) - 55.16 (1.32) 82.29 (5.24) 60 S6 
8.21 (1.66) 1.08 (0.02) - 2.51 (0.04) 1.17 (0.05) 4.23 (0.23) - 60.56 (2.12) 78.32 (2.56) 1:10 
50 
S7 
14.45 (2.07) 1.14 (0.02) 3.06 2.74 (0.11) 1.29 (0.03) 4.66 (0.17) 92.12 (2.33) 59.74 (2.01) 79.13 (1.78) 1:7.5 S8 (SD-PC) 
33.07 (1.31) 1.33 (0.01) - 3.32 (0.09) 1.35 (0.03) 5.56 (0.14) - 56.81 (1.86) 77.88 (2.91) 1:5 S9 
63.79 (3.29) 1.64 (0.03) - 4.42 (0.22) 1.38 (0.03) 7.16 (0.45) - 51.01 (3.26) 79.22 (4.11) 1:2.5 S10 
13.75 (0.27) 1.14 (0.01) 3.12 4.31 (0.13) 1.26 (0.11) 6.78 (0.31) 93.33 (1.29) 57.62 (2.25) 74.88 (2.43) 
1.7.5 
SD-PE-PAM 
12.62 (2.08) 1.13 (0.02) 3.09 3.12 (0.11) 1.27 (0.07) 5.28 (0.14) 93.61 (3.26) 58.22 (2.03) 79.54 (3.11) SD-DC 
14.34 (1.89) 1.14 (0.02) 3.42 4.41 (0.27) 1.28 (0.04) 7.22 (0.41) 89.04 (4.43) 51.32 (2.95) 78.13 (2.87) SD-DP 
(a): Leucine concentration calculated as weight% from the total carrier. (b): NL to carrier weight ratio (c): EE(f): encapsulation efficiency after recovery of NL  from 
SDP. Si: initial size, Sf: size following re-dispersion. D[4, 3]: the volume mean diameter and MMAD is the mass median aerodynamic diameter. Results are mean 
of three determinations (s.d.). 
 
 
 
 15 
 
3.2 Mannosylated MXF-NL 
Upon linking the biomaromolecule PAM to PE amino group (formula PE2) using the cross-
linker gluteraldehyde, the PS and PDI increased significantly to reach 379.32±3.61nm and 
0.301±0.045,respectively in PE-PAM, Table 1. This probably denoted PAM successful anchoring 
on the surface liposome surface via glutaraldehyde spacer arm.  No significant effect on drug EE%, 
while ζ decreased from -6.54 ± 0.41mV ( PE2) to -4.12± 0.32mV (PE-PAM)   due to PAM neutral 
nature contributing probably to the delocalization of the negative charge centers. Similar 
observations had been previously reported by [45]. PAM 1H-NMR spectrum, Fig.1a reveals a 
characteristic б values at 6.5 and 6.8, while PE demonstrated no characteristic signals at these б, 
Fig. 1b. The appearance of these signals in  PE-PAM spectrum, Fig.1c, in spite of their absence 
in PE characteristic spectrum Fig. 1b, confirmed the efficient coupling of PAM to NL.   
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Fig. 1: 1H-NMR spectra of: (a) PAM (b) NL-PE and (c) NL-PE-PAM. 
 
 
(a) 
(b) 
(c) 
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3.3 Morphology of MXF-NL 
TEM of NL formulae PC8, DC3 and PE-PAM, Fig. 2, show non-agglomerated  spherical 
NL with smooth surfaces. The lipid bilayers in PC and DC appeared as dark ring surrounding the 
internal brighter aqueous phase [46].  
 
 
 
 
 
 Fig. 2: Transmission elecctron microscope micrographs of selected MXF loaded NL (a) 
PC8, (b) DC3 and (c) PE-PAM. 
3.4  Preparation and characterization of SD-NLEM 
3.4.1 Effect of carrier composition  
In this study, attempts to co-spray dry the selected NL formulae with DX to provide SD-
NLEM capable of delivering the drug in the respiratory region. Using DX alone as carrier during 
spray drying, a low spray drying yield, 46.78 ± 4.39%, was obtained, Table 2. Addition of Leu to 
DX significantly increased the yield% in a concentration dependent manner reaching a 
maximum% increase of 34% in formula S5 containing 50%w/w Leu. Beyond 50% Leu 
concentration, only a slight non-significant yield increase (p>0.05) was noted. The anti-adherent 
properties of Leu probably decreased the cohesive forces between the particles and reduced the 
adhesion of the powder to the cyclone wall [47]. Increasing Leu concentration accompanied by 
decreasing DX concentration did not significantly affect %EE(f) of MXF till a 1:1 Leu/DX ratio, 
beyond which, further increase in Leu/DX ratio significantly reduced the %EE(f). The presence of 
a certain concentration of DX is important for keeping liposomal integrity during spray drying 
[48].  
X40000120 kV
100 nm
(a) (b) (c) 
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3.4.2. Effect of NL to carrier (NL/C) ratio 
Table 2 shows that there was no significant difference between the yields of the various 
formulae upon varying NL/C ratio (77.88±2.91 to 80.2± 3.93%), while maintaining Leu at 50% 
concentration. Conversely, the EE was only decreased at a NL/C ratio of 1:2.5 probably due to the 
insufficiency of the carriers to provide full protection to the NL from the spray drying effects and 
hence lipid melting and drug leakage of drug from the NL were possible. Similarly, Fig. 2S reveals 
that increasing NL/C ratio from 1:20 (S5) to 1:2.5, (S10) increased Sf/Si value from 1.03 ± 0.01 to 
1.64 ± 0.03, respectively corresponding to more than 60% increase in size .On the other hand, 
VMD was not affected by NL/C ratio and all SD-NLEM formulae was less than 8μm and the 
MMAD was less than 5μm pointing to the suitability of the system for alveolar deposition [49, 
50]. A NL/C ratio of 1:7.5 and Leu/DX ratio1:1 was selected for preparing SD-NLEM with various 
lipids compositions. 
3.4.3 Effect of NL composition 
Using NL/C ratio of 1:7.5 and Leu/DX ratio1:1 to prepare NL with different lipids 
compositions yielded SD-NLEM with good and drug AE exceeding 89.04%w/w. The protecting 
ability of the carrier was confirmed by the non- significantly different EE(f) compared to EE(i), 
Table 2. VMD values ranging from 4.66 ± 0.17 and 7.22 ± 0.41μm with low span values not 
exceeding 1.28 ± 0.04 were noticed. A desirable MMAD  less than 5μm was obtained with all 
formulae [51]. Sf/Si of all formulae was 1.13 ± 0.02 and 1.14 ± 0.02 with 12.62 ± 2.08 and 14.45 
± 2.07 % increase in size (Table2). The PS of the SD-NLEM did not vary significantly following 
storage six month, see Fig. 3S. Irrespective of the lipids used, the residual water contents in the 
SDP did not exceed 3.42%w/w with non-significant difference among the different formulae, 
Table2.  
3.4.5 Particle morphology of SD-NLEM 
Irrespective of the type of lipid used, SEM of SD-NLEM formulae, Fig.3, show spherical 
particles with corrugated surfaces and hollow structures inside indicating low density [52]. This 
morphology might be acquired from the surface active properties of Leu causing its accumulation 
on the droplets surface during spray drying. As a hydrophobic SAA, this surface layer will prevent 
 19 
 
the passage of water vapor and expand like a balloon. When the water fully evaporates, this layer 
will collapse producing the observed wrinkled structure with larger inter-particulate separation and 
low contact areas between the particles [53, 54].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: Scanning electron microscopic images of MXF–SD-NLEM: (a) S8 (SD-PC), (b) SD-
PE-PAM, (C) SD-DC and (d) SD-DP. 
 
(a) (b) 
(c) (d) 
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3.4.6 In vitro aerodynamic deposition using the twin stage glass impinger (TSI) 
The EF in all SD-NLEM exceeded 90% denoting the highly dispersible nature of the 
powders. The FPF, stage 2 deposition, varied from 66.59±4.72 to 72.08±1.07%, Fig. 4a. Good 
aerosolization properties evidenced by the high RP of 69.79±4.31 to 77.97±1.85% for the different 
SD-NLEM, Fig.4b, can be explained based on their SEM. The corrugated surface probably 
decreased inter-particulate interaction in two ways. First, the asperities prevent close contact 
between particles. Second, they may reduce the total area accessible for particle' interaction thus 
decreasing their cohesion and improving their aerosolization properties over the smooth spherical 
particles of otherwise similar physical properties [27 ]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: MXF-SD-NLEM (a) In vitro deposition data using TSI and (b) Inhalation indices. 
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 3.4.7 In vitro MXF release from SD-NLEM 
 As a hydrophilic dug, MXF (98%) was found in the release medium within 3h following 
dissolution of  pure MXF. The release profiles of all tested SD-NLEM were biphasic, showing a 
relatively fast release intial phase (burst release) over the first two hours amounting from 42.05 to 
55.77%, the initial burst release could be attributed to the drug located on the surface and 
unencapsulated within the NL. This amount was left to start the initial antibacterial drug effect in 
lung following pulmnary administration. The rate of drug release gradually decreased till~100%  
of the drug was released within 48h [55]. As shown in Fig. 4S the release rate was negligibly 
affected by SD-NLEM type and its lipid composition.        
3.4.8 Antibacterial activity of MXF- SD-NLEM 
In accordance with literature, MXF solution showed an MIC value of 0.25μg/mL against 
M. tuberculosis, Table3 [32]. Conversely, plain SD-NLEM formulae did not exhibit any 
antibacterial activity against M. tuberculosis. Table 4 shows that SD-DP and SD-DC showed an 
MIC value of 0.125μg/mL while the neutral SD-NLEM (SD-PC and SD-PE-PAM) exhibited MIC 
value of 0.25μg/mL similar to that of MXF solution. The two-fold decrease in MIC, in case of 
charged NL, can be owed to the increased bacterial membrane permeability induced by charged 
liposome formulation. The cationic NL interacted electrostatically with the negatively charged cell 
membrane of the mycobacteria and fused with it, enhancing antibacterial activity of the drug [56]. 
The anionic NL, with negatively charged DCP, can form hydrogen bond and/or ionic interaction 
with various bacterial membrane components i.e. saccharide moieties of various natures, 
phospholipids, glycosphingolipids, lipopolysaccharides and peptidoglycan [57]. The interaction 
and fusion of the liposomes with the bacterial cell membrane enhanced the delivery of the 
encapsulated drug and eventually improved its antibacterial effectiveness. 
3.4.10. Cytotoxicity of SD-NLEM 
As shown in Fig. 5, the encapsulation of MXF within NL did not induce major difference 
in cell cytotoxicity when compared with plain formulae. These findings, are considered good 
indicators of biocompatability and safety of the prepared formulations. Fig. 5S evidenced the 
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safety of lipids used in plain and MXF loaded SD-NLEM at different concentrations on the 
viability of A549 cells indicating the biocompatibility of the proposed nanocarrier platform. 
 
  
Fig. 5: A549 cell viability measured by MTT cytotoxicity assay  after exposure to increasing 
concentration of MXF-SD-NLEM. 
 
3.4.11. In vitro uptake study using murine mice macrophages J774A.1 
FITC loaded liposomes were prepared and spray dried using the same optimized 
conditions. The amount of FITC entrapped in NL was found to be similar in all formulae (data not 
shown). Fig. 6 shows that there was no significant difference between the fluorescent intensity  
obtained after incubating J774A.1 cells with FITC-labeled NLEM, at two different lipid 
concentrations (75 and 150 μg/mL), for 3h. At 75 μg/mL of lipid, all SD-NLEM exhibited 
significantly higher median FI compared to the control and that SD-PE-PAM showed the highest 
one.  
Fig. 7 shows increase in fluorescence level in J774A.1 with time only with the charged 
liposomal formulations SD-DC and DP. Furthermore, SD-DC and SD-DP exhibited higher mean 
FI compared to the neutral NL, (SD-PC) denoting the higher macrophage uptake of charged 
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liposomes. Cationic liposomes can interact electrostatically with negatively charged cell 
membranes and cell surface proteoglycans facilitating their cellular uptake [58]. Vyas and co-
workers reported a 3.4-fold increase in lung retention of rifampicin following its encapsulation in 
anionic liposomes composed of PC, DCP and CH while only 1.3-fold increase was noted when 
encapsulated in the corresponding neutral liposomes compared to free drug solution [59] . 
 Although SD-PE-PAM possessed very low negative ζ, nearly neutral, but it showed the 
highest mean FI with 3.4, 2.32, and 1.6-fold increase in mean FI compared to SD-PC, SD-DP and 
SD-DC respectively after 3h incubation with J774A.1 cells. Moreover, no time dependence uptake 
was seen with non-significant difference between the FI at 0.5 and 3h. This fast preferential uptake 
of SD-PE-PAM might be ascribed to mannosylation as specific receptors of mannose are presented 
on the surface of AMs [1]. This result agreed with the findings obtained by Chono and co-workers 
who studied the effect of surface mannose modification on aerosolized liposomes delivery to AM 
[60]. Other investigators reported similar results upon mannosylation of solid lipid nanoparticles 
[61]  and polypropyleneimine dendrimers [62]. 
3.4.12. In vivo pulmonary deposition of SD-NLEM 
 One representative formula (SD-PC) was selected for studying the in vivo deposition 
pattern following intrapulmonary administration of fluorescent SD-NLEM using DPI from Penn-
century®. Fig. 8a shows the green fluorescence of FITC- SD-NLEM. The auto-fluorescence of the 
rat lung was found to be low except in the peripheral regions where pulmonary artery gave a bright 
auto-fluorescence as shown in Fig. 8b [63]. Few fluorescently green particles appeared in the 
trachea and bronchus, Fig. 8c and d, while several green spots were evident in the alveolar ducts 
and spaces, Fig. 8e and f. This indicated that the developed SD-NLEM were localized mainly in 
the alveolar spaces and nearly absent or showed very low deposition in the upper respiratory tract 
(trachea and bronchi). From a therapeutic point of view, the deposition of high percentage SD-
NLEM in alveolar space is so important as it is the site where mycobacterium tuberculosis (M. 
tuberculosis) can reside  and survive for extended period of time [5]. 
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Fig. 6: Flow cytometry diagram of (a) control murine macrophages (J774A.1) and murine 
macrophages (J774A.1) after exposure for 3h to (b) SD-PC, (c) SD-PE-PAM, (d) SD-DC and 
(e) SD-DP at different lipid concentrations. 
 
 
 
 
Fig. 7: (a) Median fluorescence intensity obtained after incubation of J774A.1 cells with 
selected fluorescently labeled MXF-NL formulae for 3h using a lipid concentration of 75 
µg/mL and (b) Mean fluorescence intensity obtained after incubation of J774A.1 cells with 
different MXF-SD-NLEM formulae for different time intervals. 
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4. Conclusion 
At a PC/CH ratio of 7:3, NL exhibited the highest EE% and lowest PDI with a small PS. 
The antibacterial activity of MXF against M. tuberculosis was maintained by encapsulation in 
liposomes and was enhanced upon using charged liposomes. The chosen spray drying parameters 
and the selected excipients guaranteed low moisture content in SD-NLEM and enhanced the 
physical stability of liposomes. In vitro data, substantiated by in vivo studies, confirmed that the 
PS and morphological characteristics of the spray dried powders allowed for high deposition of 
the particles in the alveolar region where the microorganism resides. The presence of DCP and 
DOTAP potentiated the drug anti- mycobacterial activity. PAM surface decoration enhanced the 
active uptake by alveolar macrophages. Using this passively targeted carrier system, to actively 
target to the most difficult infection where the micro-organism is hidden in the macrophages. The 
enhanced stability, therapeutic efficiency, and improved deep lung deposition, evidenced by in 
vivo data, elected the system for use in severe cases of intracellular diseases. 
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Fig. 8: Fluorescent microscopic images of (a) FITC labeled SD-NLEM (Formula S8) and (b) 
rat lung tissue (control) (The bright region corresponds to the pulmonary artery) and in vivo 
deposition of FITC labeled SD-NLEM (SD-PC) in rat lung sections (c) trachea, (d) bronchia, 
(e) and (f) alveolar ducts. The images are representative of 3-5 slides per each area, scale bar 
represents 20 µm.  
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